CA2816437A1 - Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1) - Google Patents

Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1) Download PDF

Info

Publication number
CA2816437A1
CA2816437A1 CA2816437A CA2816437A CA2816437A1 CA 2816437 A1 CA2816437 A1 CA 2816437A1 CA 2816437 A CA2816437 A CA 2816437A CA 2816437 A CA2816437 A CA 2816437A CA 2816437 A1 CA2816437 A1 CA 2816437A1
Authority
CA
Canada
Prior art keywords
seq
antibody
chain variable
antigen binding
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2816437A
Other languages
English (en)
Inventor
Gilles Bernard Tremblay
Mario Filion
Traian Sulea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alethia Biotherapeutics Inc
Original Assignee
National Research Council of Canada
Alethia Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2009/001586 external-priority patent/WO2010060186A1/fr
Application filed by National Research Council of Canada, Alethia Biotherapeutics Inc filed Critical National Research Council of Canada
Priority to CA2816437A priority Critical patent/CA2816437A1/fr
Priority claimed from PCT/CA2010/001795 external-priority patent/WO2011054112A1/fr
Publication of CA2816437A1 publication Critical patent/CA2816437A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
CA2816437A 2009-11-03 2010-11-03 Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1) Abandoned CA2816437A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2816437A CA2816437A1 (fr) 2009-11-03 2010-11-03 Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CA2009/001586 WO2010060186A1 (fr) 2008-11-03 2009-11-03 Anticorps qui bloquent spécifiquement l’activité biologique d’un antigène tumoral
CAPCT/CA2009/001586 2009-11-03
CA2816437A CA2816437A1 (fr) 2009-11-03 2010-11-03 Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1)
PCT/CA2010/001795 WO2011054112A1 (fr) 2009-11-03 2010-11-03 Anticorps inhibant de façon spécifique l'activité biologique de l'antigène 1 associé au rein (kaag1)

Publications (1)

Publication Number Publication Date
CA2816437A1 true CA2816437A1 (fr) 2011-05-12

Family

ID=48570547

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2816437A Abandoned CA2816437A1 (fr) 2009-11-03 2010-11-03 Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1)

Country Status (1)

Country Link
CA (1) CA2816437A1 (fr)

Similar Documents

Publication Publication Date Title
US20180369269A1 (en) Antibodies that specifically block the biological activity of a tumor antigen
US10597450B2 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
EA035947B1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011054112A1 (fr) Anticorps inhibant de façon spécifique l'activité biologique de l'antigène 1 associé au rein (kaag1)
CA2816437A1 (fr) Anticorps inhibant de facon specifique l'activite biologique de l'antigene 1 associe au rein (kaag1)
NZ615694B2 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130404

FZDE Dead

Effective date: 20170720